IP Library Granted Patent US 12,201,618
Granted Patent B2
US 12,201,618 · App. 17/151,577 · Granted Jan 21, 2025

Use of riluzole prodrugs to treat Alzheimer's disease

Inventors: Vladimir Coric (Madison, CT); Robert Berman (New Haven, CT); Irfan Qureshi (Hackensack, NJ)
Assignee: Biohaven Therapeutics Ltd.
A61K31/428A61K9/48A61P25/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,201,618
App. No.
17/151,577
Granted
Jan 21, 2025
Kind
B2
Abstract

Disclosed are methods of treating Alzheimer's Disease by administering to a patient in need thereof a riluzole prodrug such as troriluzole. Pharmaceutical compositions and kits including the riluzole prodrugs are also disclosed.

Claims (17)

1. A method of treating Alzheimer's Disease of mild to moderate severity in a patient in need thereof, the method comprising administering to the patient a riluzole prodrug having the following formula:

wherein the riluzole prodrug is administered to the patient at a dosage of 280 mg once per day or a dosage of 140 mg twice per day.

2. The method of claim 1 , wherein the riluzole prodrug is administered to the patient in the form of a capsule.

3. The method of claim 1 , wherein the riluzole prodrug is administered to the patient for a duration of from the onset of treatment to the end of the patient's life.

4. A method for improving a response in a patient afflicted with Alzheimer's disease of mild to moderate severity, the method comprising administering to the patient in need thereof, an effective amount of a riluzole prodrug having the following formula:

wherein the riluzole prodrug is administered to the patient at a dosage of 280 mg once per day or at a dosage of 140 mg twice per day.

5. The method of claim 4 , wherein the improved response is one or more of overall survival, quality of life, overall response rate, duration of response, delay of onset, or patient reported outcome.

6. A kit for treating a patient afflicted with Alzheimer's Disease of mild to moderate severity, the kit comprising:

(a) a riluzole prodrug; and

(b) instructions for administering the riluzole prodrug in the method of claim 1 ,

wherein the riluzole prodrug has the following formula:

wherein a daily dosage of the riluzole prodrug in the kits is 280 mg.

7. A kit for improving a response in a patient afflicted with Alzheimer's Disease of mild to moderate severity, the kit comprising:

(a) a riluzole prodrug; and

(b) instructions for administering the riluzole prodrug in the method of claim 4 ,

wherein the riluzole prodrug has the following formula:

wherein a daily dosage of the riluzole prodrug in the kit is 280 mg.

Assignments (3)
SECURITY INTEREST Recorded May 1, 2025
From: BIOHAVEN THERAPEUTICS LTD
To: BEETLEJUICE SA LLC, AS PURCHASER AGENT
Reel/Frame 071147/0260 →
RELEASE OF SECURITY INTEREST Recorded Apr 27, 2025
From: SIXTH STREET SPECIALTY LENDING, INC.
To: BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.; BIOHAVEN THERAPEUTICS LTD.; BIOHAVEN PHARMACEUTICAL IRELAND DESIGNATED ACTIVITY COMPANY
Reel/Frame 071083/0330 →
PATENT SECURITY AGREEMENT Recorded Dec 2, 2021
From: BIOHAVEN THERAPEUTICS LTD.
To: SIXTH STREET SPECIALTY LENDING, INC., AS ADMINISTRATIVE AGENT
Reel/Frame 058299/0273 →
Continuity (3)
Continuation In Part 17261057
Provisional Application 62701814 · Jul 22, 2018
Related Publication 20210212999A1 · Jul 15, 2021
References Cited (12)
US 10485791B2 · Wrobel · 2019 [cited by examiner]
US 10639298B2 · Wrobel · 2020 [cited by examiner]
US 10905681B2 · Wrobel · 2021 [cited by examiner]
US 11052070B2 · Wrobel · 2021 [cited by examiner]
US 20130064775A1 · Busserolles et al. · 2013 [cited by applicant]
US 20180037557A1 · Wrobel et al. · 2018 [cited by applicant]
WO 2015089049A1 · 2015 [cited by applicant]
WO WO2016140879A1 · 2016 [cited by examiner]
WO 2018031707A1 · 2018 [cited by applicant]
International Search Report dated Nov. 12, 2019 issued for the corresponding application PCT/US2019/042718 (2 pages). [cited by applicant]
Written Opinion dated Nov. 12, 2019 issued for the corresponding application PCT/US2019/042718 (4 pages). [cited by applicant]
International Preliminary Report on Patentability dated Nov. 12, 2019, issued for the corresponding application PCT/US2019/042718 (5 pages). [cited by applicant]